BIIB Stock Analysis: Biogen Inc
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM,
- Latest close
- $219.88
- 20-day change
- -2.06%
- Trend state
- BULLISH
- Classification
- Healthcare · Drug Manufacturers - General
Market context
Biogen Inc moved -2.06% over the latest 20-session window. BullRecon currently classifies the broader setup as BULLISH.
Latest report
The latest cached company filing period (FY2025 · $9.9B revenue · $1.3B net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Health is currently the strongest dimension at 5.2/6, while Growth is the lowest at 2.5/6. Scores are comparative research signals, not forecasts.